IPILIMUMAB PLUS LENALIDOMIDE FOR TREATMENT OF RELAPSED DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) IN PATIENTS (PTS) WITH LYMPHOID MALIGNANCIES
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.124_2630
Abstract: vation of CD56+ NKC as opposed to NR (Figure 1). NKC cytotoxicity through the expression of Granzyme B was seen in R vs NR. Flow quantitation of circulating CD4+ CD25+ T cells (Tregs) shows a… read more here.
Keywords: plus lenalidomide; ipilimumab plus; relapsed disease; lenalidomide treatment ... See more keywords
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-3648
Abstract: Purpose: In RE-MIND2 (NCT04697160), patient-level outcomes from the L-MIND study (NCT02399085) of tafasitamab plus lenalidomide were retrospectively compared with patient-level matched observational cohorts treated with National Cancer Care Network (NCCN)/European Society for Medical Oncology (ESMO)-listed… read more here.
Keywords: plus lenalidomide; tafasitamab plus; versus systemic; lenalidomide versus ... See more keywords
Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.8015
Abstract: 8015Background: The PD-1 inhibitor pembro blocks interaction of PD-1 with its ligands PD-L1/PD-L2, activating antitumor immunity. Combination of pembro, len, and dex may provide synergistic antitum... read more here.
Keywords: lenalidomide len; dex; pembro; plus lenalidomide ... See more keywords
Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.tps7094
Abstract: TPS7094 Background: FL and MZL are indolent B-cell non-Hodgkin lymphomas (B-NHLs) that are treated in a similar way in the R/R setting. Despite the efficacy of rituximab–lenalidomide (R2) in patients (pts) with R/R FL, and… read more here.
Keywords: mzl; part; lymphoma; plus lenalidomide ... See more keywords
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study
Sign Up to like & getrecommendations! Published in 2025 at "Haematologica"
DOI: 10.3324/haematol.2024.287141
Abstract: Tafasitamab combined with lenalidomide was approved in Europe in 2021 for transplant-ineligible patients with relapsed/ refractory diffuse large B-cell lymphoma. Approval was based on the L-MIND study, which demonstrated a 57.5% overall response rate (ORR),… read more here.
Keywords: real world; response; tafasitamab plus; cell ... See more keywords